Literature DB >> 8462281

Inhibition of epoxide hydrolase from human, monkey, bovine, rabbit and murine liver by trans-3-phenylglycidols.

E C Dietze1, J Casas, E Kuwano, B D Hammock.   

Abstract

1. trans-3-Phenylglycidols were potent inhibitors of cytosolic epoxide hydrolases in all species tested. 2. The order of inhibitor potency varied from species to species but trans-3-(4-nitrophenyl)glycidols were always the most potent inhibitors tested for cytosolic epoxide hydrolase. 3. The S,S-enantiomer was a more potent cytosolic epoxide hydrolase inhibitor than the R,R-enantiomer when a free hydroxyl group was present. However, (2R,3R)-1-benzoyloxy-2,3-epoxy-3-(4-nitrophenyl)propane was always a better inhibitor than the (2S,3S)-enantiomer. 4. All microsomal epoxide hydrolases were poorly inhibited by the trans-3-phenylglycidols, and related compounds, tested. The best new microsomal epoxide hydrolase inhibitor tested was (1S,2S)-1-phenylpropylene oxide which gave 18-63% inhibition, at 2 mM, depending on the species tested.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8462281     DOI: 10.1016/0305-0491(93)90373-d

Source DB:  PubMed          Journal:  Comp Biochem Physiol B        ISSN: 0305-0491


  3 in total

1.  Detoxification of environmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase.

Authors:  M A Argiriadi; C Morisseau; B D Hammock; D W Christianson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  Characterization of epoxide hydrolase activity in Alternaria alternata f. sp. lycopersici. Possible involvement in toxin production.

Authors:  F Pinot; E D Caldas; C Schmidt; D G Gilchrist; A D Jones; C K Winter; B D Hammock
Journal:  Mycopathologia       Date:  1997       Impact factor: 2.574

Review 3.  Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis.

Authors:  Ryan D Jones; Jie Liao; Xin Tong; Dandan Xu; Leyu Sun; Haonan Li; Guang-Yu Yang
Journal:  Front Pharmacol       Date:  2019-06-25       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.